Recent News

• 03.04.2025 - Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
• 02.06.2025 - Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
• 02.05.2025 - Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
• 02.05.2025 - Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
• 01.09.2025 - Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Recent Filings

• 02.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.07.2025 - 8-K Current report
• 02.07.2025 - EX-99.1 EX-99.1
• 02.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2025 - 3 Initial statement of beneficial ownership of securities
• 02.03.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.29.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities